Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.65 |
| ▸ | MAPT | P10636 | 10/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | GCGR | P47871 | 1/20 | 0.59 |
| ▸ | CCR6 | P51684 | 1/20 | 0.58 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292676 | 1.00 | PHGDH (1.00) | PHGDHMEN1KMT2AKDM4EMAPT | |
| SCHEMBL14583880 | 1.00 | PHGDH (1.00) | PHGDHMEN1KMT2AKDM4EMAPT | |
| SCHEMBL12766815 | 0.87 | MEN1 (0.78) | PHGDHMEN1KMT2AKDM4EMAPT | |
| SCHEMBL1638695 | 0.87 | MEN1 (0.78) | PHGDHMEN1KMT2AKDM4EMAPT | |
| SCHEMBL1638698 | 0.87 | MEN1 (0.78) | PHGDHMEN1KMT2AKDM4EMAPT | |
| SCHEMBL21292817 | 0.85 | PHGDH (0.74) | PHGDHMEN1KMT2AMAPTTDP1 | |
| SCHEMBL16035055 | 0.85 | PHGDH (0.79) | PHGDHMEN1KMT2AKDM4EMAPT | |
| SCHEMBL21292815 | 0.85 | PHGDH (0.74) | PHGDHMEN1KMT2AMAPTTDP1 | |
| SCHEMBL21292819 | 0.85 | PHGDH (0.79) | PHGDHMEN1KMT2AKDM4EMAPT | |
| SCHEMBL14983731 | 0.84 | MEN1 (0.77) | PHGDHMEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12628858-B2 | Therapy for colorectal and small intestine cancers | CORNELL UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2023237873-A1 | TARGETS FOR CANCER THERAPY | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2023-12-14 | — | — | WO | disclosed |
| US-20230100559-A1 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-03-30 | — | — | US | disclosed |
| US-20220400732-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | CORNELL UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| CN-110392681-B | Tosylacetate-based compounds and derivatives thereof as PHGDH inhibitors | 勃林格殷格翰国际有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| EP-3942023-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | The Broad Institute, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220400732-A1 | ANTI-FRUCTOSE THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | KHK, GCK, FN3K | PHGDH 275/4885MEN1 2992/4885KMT2A 1229/4885 |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | PHGDH 1/4885MEN1 190/4885KMT2A 1325/4885 |
| US-20230100559-A1 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | SHMT2, PC, ME2 | PHGDH 94/4885MEN1 2816/4885KMT2A 2535/4885 |
| US-12628858-B2 | Therapy for colorectal and small intestine cancers | FABP2, PKN2, APC | PHGDH 203/4885MEN1 2799/4885KMT2A 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.